Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | ENO1 | P06733 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16472466 | 0.88 | POLB (0.36) | POLBCYP2D6MAPK1CYP2C19HSD17B10 | |
| SCHEMBL16472470 | 0.88 | POLB (0.36) | POLBCYP2D6MAPK1CYP2C19HSD17B10 | |
| SCHEMBL26665869 | 0.88 | POLB (0.36) | POLBCYP2D6MAPK1CYP2C19HSD17B10 | |
| SCHEMBL10210462 | 0.79 | PIK3CD (0.37) | POLBDPP4DPP8DPP7 | |
| SCHEMBL10160242 | 0.78 | PER2 (0.37) | POLBDPP4DPP8DPP7 | |
| SCHEMBL19770241 | 0.76 | DPP4 (0.32) | POLBDPP4DPP8DPP7 | |
| SCHEMBL28357684 | 0.73 | CA1 (0.40) | POLBDPP4DPP8DPP7 | |
| SCHEMBL25667733 | 0.73 | MT-CO2 (0.39) | POLBDPP4DPP8DPP7 | |
| SCHEMBL10210455 | 0.72 | PIK3CD (0.42) | POLBDPP4DPP8DPP7 | |
| SCHEMBL22702323 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265620-A1 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION CONTAINING SAME, AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | POLB 3747/4885DPP4 3860/4885ENO1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.